Neoadjuvant concurrent chemoradiation (CCRT) is standard treatment for clinical stage II/III rectal cancers. However, whether patients with pathological complete response (pT0N0, pCR) should receive adjuvant chemotherapy and whether delayed surgery will influence the pCR rate remains controversial. A nationwide population study was conducted using the Taiwan Cancer Registry Database from January 2007 to December 2013. Kaplan-Meier survival analysis was performed. Cox proportional hazards models were used to estimate multivariate adjusted hazard ratios (HR) and 95% confidence intervals (95% CI). Of the 1,914 patients who received neoadjuvant CCRT, 259 (13.6%) achieved pCR and had better survival (adjusted HR: 0.37, 95% CI: 0.24-0.58; p < 0.001). The cumulative rate of pCR rose up to 83.4% in the 9th week and slowly reached a plateau after the 11th week. Among the patients with pCR, those who received adjuvant chemotherapy had no survival benefits compared to those without adjuvant chemotherapy (adjusted HR: 0.72, 95 CI: 0.27-1.93; p 5 0.52). By subgroup analysis, those younger than 70-year old and received adjuvant chemotherapy had better survival benefit than those without adjuvant chemotherapy (adjusted HR: 0.19, 95% CI: 0.04-0.97; p 5 0.046). Delayed surgery by 9-12 weeks after the end of neoadjuvant CCRT can maximize the pCR rate, which is correlated with better survival. Adjuvant chemotherapy may be considered in patients with pCR and aged <70-year old, but further prospectively randomized controlled trials are warranted to validate these findings.
Colorectal cancer is the third most common cancer in men and the second in women worldwide. 1 Rectal cancers make up approximately one-fourth of large bowel cancers. 2, 3 Treatment includes radiation, surgery and chemotherapy. Concurrent chemoradiation (CCRT) is often used for patients with clinical stage II or III rectal cancers. In many clinical trials, 50-60% of patients are down-sized after neoadjuvant therapy, with 15-27% of patients showing pathological complete response (pCR) or ypT0N0. [4] [5] [6] [7] [8] [9] [10] In literature, those with pCR after CCRT and curative surgery have better long-term outcomes. 9, [11] [12] [13] [14] However, although current guidelines suggest adjuvant chemotherapy for patients with pCR based on extrapolated data for colon cancer and meta-analysis, the benefit of adjuvant chemotherapy remains unclear in patients with pCR after neoadjuvant CCRT and surgery due to lack of prospective data. 15, 16 There is also paucity of data on Asian patients.
In Taiwan, colorectal cancer has the highest incidence among other cancers, in which rectal cancer accounts for 35.8%.
aimed to elucidate the prognosis of patients with pCR and determine if adjuvant chemotherapy has survival benefits.
Materials and Methods
Data source and search strategy Hospitals with >50 beds are required to submit information on newly diagnosed cancer patients to the TCR yearly. The TCR then reimburses the hospitals based on the numbers of cases reported so as to reduce the likelihood of under-reporting.
All cancer registry databases in the TCR have been converted to International Classification of Diseases, the 9th Revision Codes (ICD9) and the 3rd Edition of International Classification of Disease for Oncology (ICD-O-3) and linked to the death certificates from the National Death Database. For the purpose of this study, persons not identified as mortality were considered to be alive (passive follow-up).
The Institutional Research Ethics Committee of the National Health Research Institutes approved this study.
Inclusion and exclusion criteria
Patients with metastatic disease upon diagnosis, who did not undergo surgery, or who had non-adenocarcinoma histology were excluded. Eligible cases were: (i) patients with newly diagnosis coding with ICD-O-3 of C199 (rectum), C209 (rectum) (ii) those with clinical stage II and III (the stage was converted according to TNM classification version 7, AJCC); and (iii) those who received both neoadjuvant 5-Fluorouracil based CCRT (including 5-Fluorouracil/leucovorin, Tegafur or Capecitabine; with RT dose ranged from 4,000 to 6,000 cGy) and curative surgery.
Statistical analysis
The v 2 (Fisher's exact) tests and independent t tests were used to determine differences in demographic characteristics between patients with and those without pCR. The effect of pCR and adjuvant chemotherapy on overall survival was examined using the Kaplan-Meier analysis and the results were compared by log-rank test. To examine the association between pCR and adjuvant chemotherapy and overall survival while controlling for other clinical (e.g., clinical T stage, clinical N stage, time interval, operation and with or without adjuvant chemotherapy) and demographic (e.g., age and sex) variables, Cox proportional hazards models were applied. Significance was set at p < 0.05 for two-tailed and point estimates with a 95% confidence interval (CI). All calculations were performed using the SAS version 9.3 (SAS Institute, Cary, NC) and SPSS version 21.0 (SPSS, Chicago, IL).
Results

Demographic data stratified by pCR status and adjuvant chemotherapy
There was a total of 1,914 patients with clinical stage II and III rectal adenocarcinoma who received neoadjuvant CCRT and curative resection. Their median follow-up time was 37 months. Among them, 259 (13.6%) achieved pCR, 44% of whom received adjuvant chemotherapy (Fig. 1 ). Patients without pCR had higher grade, more advanced clinical T/N stage, higher rate of abdomino-perineal resection (APR) and received more adjuvant chemotherapy compared to those 
What's new?
Neoadjuvant concurrent chemoradiation (CCRT) followed by surgery is the standard treatment for stage II and III rectal cancer. However, the benefit of adjuvant chemotherapy for patients with pathological complete response (pCR) and the timing of surgery after the end of neoadjuvant CCRT have been debated. Using a nationwide population dataset in Taiwan, this study confirms that pCR predicts better overall survival. The findings also suggest that delaying surgery by 9 to 12 weeks after the end of neoadjuvant CCRT can boost pCR rate and that adjuvant chemotherapy may potentially be considered in patients with pCR and aged <70-year old. with pCR (Table 1) . Patients received irradiation with dose exceeding 51 Gy were <7% in both non-pCR and pCR patients (5.3% vs. 6.6%). The time interval from the end of CCRT to curative resection was longer in patients with pCR (<6 vs. 6 weeks, p 5 0.03). Age, sex, examined regional lymph nodes and total radiation dose were not different between these two populations ( Table 1) . Among patients with pCR, those who received adjuvant chemotherapy were younger (56.67 6 13.04 years, p < 0.01) and received RT dose <51 Gy (97.4%, p 5 0.02), but there was no significant difference in sex, grade and clinical T and N stage ( Table 2) .
Time interval between the end of neoadjuvant CCRT nd curative resection and its impact on pCR
There were 259 patients with pCR after CCRT and curative resection. Their cumulative incidence of pCR in terms of time interval between CCRT and surgery (Fig. 2a , Supporting Information Table 1 ) revealed that the cumulative rate of pCR surged rapidly on the 5th week and rose up to 83.4% in the 9th week and 93.8% in the 11th week. After the 11th week, the cumulative rate of pCR slowly reached a plateau. The number of pCR in the interval between the end of CCRT and surgery was 18.8, 22.7, 18.2 and 20% in the 9th, 11th, 13th and 15th week, respectively (Fig. 2b, Supporting Information Table 2 ).
Overall survival analysis by pCR status and adjuvant chemotherapy
The 5-year overall survival rate was significantly better in patients with pCR than in those without pCR (90% vs. 69%, p < 0.001) (Fig. 3a) . In mutivariate analysis adjusted for age, sex, clinical stage, regional lymph node examined, time interval from CCRT to surgery and type of surgery and adjuvant chemotherapy, pCR was significantly associated with better overall survival (adjusted HR: 0.37, 95 CI: 0.24-0.58; p < 0.001) ( Table 3 ). Among patients with pCR, those who received adjuvant chemotherapy did not have better overall survival than those with no adjuvant chemotherapy (adjusted HR: 0.72, 95 CI: 0.27-1.93; p 5 0.52) ( Table 3 ; Fig. 3b) .
However, after adjusting for sex, clinical stage, regional lymph node examined, time interval from CCRT to surgery and type of surgery, adjuvant chemotherapy was associated with better overall survival in patients aged 70 years (adjusted HR: 0.19, 95% CI: 0.04-0.97; p 5 0.046) but not in those aged >70 years (adjusted HR: 2.40, 95% CI: 0.53-10.7; p 5 0.25) ( Table 3 ). 
Discussion
To date, this study is the first nationwide study among Asian population that has clarified the association between pCR and long-term prognosis and if adjuvant chemotherapy improved survival among patients with clinical stage II/III rectal cancer after neoadjuvant CCRT. Recently, Al-Sukhni et al. reported a pCR rate of 23.3% after neoadjuvant CCRT in a retrospective review of a national cancer database (NCDB). 6 Wasmuth et al. also reported a pCR rate of 12.7% after neoadjuvant CCRT and curative surgery based on the colorectal cancer registry of Norway. 13 Their findings were similar to the pCR rate (13.4%) in our study. But the role of adjuvant chemotherapy was not addressed in both large-scale population studies. In the Norwegian study, patients with pCR tended to be younger (p 5 0.003). In the current study, conversely, age and sex were not significant for pCR and this was compatible with results of other large-scale meta-analysis and population studies. 6, 8, 9, 11, 12 As in other studies, lower tumor grade and T/N and clinical stage were associated with higher pCR, which was associated with better long-term survival. 9, [11] [12] [13] [14] The 2013 NCCN guidelines regarding rectal cancer suggested delayed surgery by up to 5-10 weeks after the end of CCRT. In the 2016 version, the guideline recommended to further delay surgery up to 5-12 weeks to boost the pCR rate, 15, [18] [19] [20] [21] [22] [23] despite the fact that literature indicated increased pelvic fibrosis and post-operative morbidity with longer interval after CCRT. 24 The current study also indicates that delayed surgery after CCRT may be attributed to tumor down-sizing and the increase of pCR rate (Figs. 2a and 2b) . The highest pCR occurred on the 11th Week (22.7%), similar to those in other large scale study (19.7%) . 20 In our study, surgery was suggested to be delayed by 9-12 weeks after the end of neoadjuvant CCRT to maximize pCR rate in patients with clinical stage II/III rectal cancers.
Due to a lack in prospective studies on rectal cancer, adjuvant chemotherapy remains controversial in patients with pCR. Adjuvant therapy is not the standard in patients with pCR in real world practice, as seen in this study (44% with adjuvant chemotherapy vs. 56% without). 25, 26 According to recent meta-analysis on rectal cancers, patients with pCR may not benefit from adjuvant chemotherapy in survival, 27 which parallels the findings here. However, the patient number (n 5 259) may be too small in this study to reach a solid conclusion. In subset analysis, adjuvant chemotherapy is Because of its retrospective design, this study has several limitations. First, important clinical factors like performance status, co-morbidities, peri-operative complications, postoperative morbidity, the time and treatment for relapsed disease and chemotherapy dose and schedule (such as adjuvant chemotherapy with 5-Fluorouracil/leucovorin, Tegafur, Capecitabine or oxaliplatin-containing regimen and dose) are not available in the TCRD. Besides, the accuracy of pre-treatment staging is also a limitation in our study. Pelvic MRI or CT 6 endoscopic ultrasound are mandatory for precise staging. However, this was not recorded in the TCRD, and the clinical stage was provided by corresponding hospitals with consensus guideline for image study. Patients with pCR but poor PS after neoadjuvant CCRT and curative resection may not receive adjuvant chemotherapy at all. How these important factors confound overall survival is beyond the scope of this study. In addition, patients with pCR receiving adjuvant chemotherapy were younger than those without adjuvant chemotherapy. How age and co-morbidities further impact the overall survival from adjuvant chemotherapy was also not investigated.
Conclusions
Neoadjuvant CCRT and curative surgery remain the standard treatment for patients with clinical stage II and III rectal cancers. The findings confirm that pCR predicts better overall survival. Delaying surgery by 9 to 12 weeks after the end of neoadjuvant CCRT can boost pCR rate. Adjuvant chemotherapy in patients with pCR does not improve survival but may provide survival benefits in patients aged 70 years. Further prospectively randomized controlled trials are needed to validate the findings.
